LEK D.D Pharmaceutical Import Profile — Slovenia (DGFT 2022–2026)

Name: LEK D.D Pharmaceutical Import Records from India — 8 Products, $25.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

LEK D.D — Pharmaceutical Importer Profile (2026) | 8 Products, $25.9M Trade | TransData Nexus

LEK D.D

Pharmaceutical Importer · Slovenia · Immunosuppressants Focus · $25.9M Total Trade · DGFT Verified

LEK D.D is a pharmaceutical importer based in Slovenia with a total trade value of $25.9M across 8 products in 6 therapeutic categories. Based on 518 verified import shipments from Indian Customs (DGFT) records, LEK D.D is the #1 buyer in 1 product including Loratadine. LEK D.D sources from 2 verified Indian suppliers, with Sandoz Private Limited accounting for 100.0% of imports.

LEK D.D — Import Portfolio & Supplier Network

LEK D.D import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to LEK D.D?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sandoz Private Limited	$9.2M	263	100.0%
Clearsynth Labs Limited	$3.8K	3	0.0%

LEK D.D sources from 2 verified Indian suppliers across 187 distinct formulations. The sourcing is highly concentrated — Sandoz Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does LEK D.D Import?

Formulation	Value	Ships
Gabapentin hgc 300MG in91 sh eu 03 material no. -	$400.0K	8
Desloratadine fct 5MG in91 sh eu 07	$200.0K	4
Clopidogrel hcl fct 75MG in91 sh eu 04	$200.0K	4
Gabapentin hgc 300MG in91 sh eu 05 material no	$200.0K	4
Tacrolimus hgc 1MG in91 sh eu 04	$150.0K	3
Tacrolimus hgc 05MG in91 sh eu 06	$150.0K	3
Mycophen mof hgc 250MG in91 sh eu 05 material no. -	$150.0K	3
Tacrolimus hgc 5MG in91 sh eu 03 material no. -	$150.0K	3
Tacrolimus hgc 1MG in91 sh eu 04 material no. -	$150.0K	3
Valsart hct fct 160 25MG in91 sh eu 03 material no	$142.6K	3
Gabapentin hgc 400MG in91 sh eu 05 material no	$120.9K	3
Gabapentin hgc 100MG in91 sh eu 03 material no. -	$111.7K	4
Material no. - 42028358 gabapentin hgc 100MG in91 sh eu	$108.7K	3
Tacrolimus hgc 5MG in91 sh eu 03	$100.0K	2
Valsart hct fct 320 12 5MG in91 sh eu 03material no	$100.0K	2

LEK D.D imports 187 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tacrolimus	Immunosuppressants	$10.7M	213	4.9%	4
2	Gabapentin	CNS & Psychiatric	$5.5M	110	0.6%	2
3	Valsartan	Cardiovascular	$3.4M	67	1.7%	6
4	Loratadine	Antihistamines & Allergy	$2.1M	42	1.1%	1
5	Allopurinol	Lipid & Metabolism	$1.7M	34	0.3%	3
6	Clopidogrel	Cardiovascular	$1.6M	32	0.6%	11
7	Ezetimibe	Lipid & Metabolism	$600.0K	12	0.1%	12
8	Voriconazole	Advanced Antifungals	$400.0K	8	1.3%	9

LEK D.D imports 8 pharmaceutical products across 6 categories into Slovenia totaling $25.9M. The company is the #1 buyer for 1 product: Loratadine.

LEK D.D — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

LEK d.d., established in 1946, is Slovenia's first and oldest pharmaceutical company, specializing in the development, production, and distribution of generic pharmaceuticals, biosimilars, and active pharmaceutical ingredients. Headquartered at Verovškova ulica 57, 1526 Ljubljana, Slovenia, LEK d.d. operates as a subsidiary of Sandoz, the generic division of Novartis. This affiliation positions LEK d.d. as a significant player in the global pharmaceutical industry, particularly in the generics and biosimilars sectors.

As a member of the Sandoz Group, LEK d.d. contributes substantially to Slovenia's pharmaceutical distribution network. The company is recognized for its expertise in technologically complex projects, playing a pivotal role in shaping the Slovenian, European, and global research and development landscapes. With a workforce of approximately 1,001 to 5,000 employees, LEK d.d. is a key contributor to the Slovenian economy, generating about 2.2% of the national GDP.

2Distribution Network

LEK d.d. maintains a robust distribution network within Slovenia and extends its reach to nearly 60 international markets. The company's logistics capabilities are supported by its affiliation with Sandoz, ensuring efficient supply chain management and distribution. While specific warehouse locations are not publicly disclosed, LEK d.d.'s extensive distribution network underscores its capacity to meet both domestic and international demand effectively.

3Industry Role

In Slovenia's pharmaceutical supply chain, LEK d.d. functions primarily as a manufacturer and distributor of generic pharmaceuticals and biosimilars. While the company imports certain finished pharmaceutical formulations, its core operations focus on the production and distribution of these products. LEK d.d. is not identified as a wholesaler, parallel importer, hospital supplier, or logistics intermediary within the Slovenian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — LEK D.D

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

LEK d.d.'s sourcing strategy exhibits a high degree of concentration, with a significant reliance on a single supplier, Sandoz Private Limited, accounting for $9.2 million of the total $25.9 million in imports from India. This dependency suggests a strategic choice to maintain a streamlined supply chain and ensure consistent product quality. The stability of this relationship is evidenced by the substantial number of shipments (263) and the exclusive nature of the sourcing arrangement. However, the minimal engagement with other suppliers, such as Clearsynth Labs Limited, indicates limited diversification in sourcing. This concentrated approach may pose risks related to supply chain disruptions or changes in supplier dynamics.

2Supply Chain Resilience

LEK d.d.'s supply chain resilience concerning Indian imports appears robust, primarily due to its exclusive relationship with Sandoz Private Limited. The substantial volume of imports and the high number of shipments suggest a stable and reliable supply chain. However, the limited number of suppliers and formulations imported indicates a lack of diversification, which could impact the company's ability to adapt to supply chain disruptions or shifts in market demand. The regulatory compliance of Sandoz Private Limited, as a subsidiary of Sandoz, is likely to meet international standards, further enhancing supply chain reliability.

Importing Pharmaceuticals into Slovenia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Slovenia

1Regulatory Authority & Framework

In Slovenia, the Agency for Medicinal Products and Medical Devices (JAZMP) serves as the primary regulatory authority overseeing the pharmaceutical sector. The importation of medicinal products is governed by the Medicinal Products Act and the Rules on the Manufacture, Wholesale Distribution, and Import of Active Substances. These regulations stipulate that only entities with a manufacturing authorization for medicinal products, which includes import activities, are permitted to import such products into Slovenia. (jazmp.si)

2Import Licensing & GMP

Import licensing in Slovenia requires entities to hold a manufacturing authorization for medicinal products, encompassing import activities. This authorization is granted by JAZMP and is essential for the legal importation of medicinal products. Regarding Good Manufacturing Practice (GMP) certification, Slovenia recognizes EU GMP, WHO GMP, and PIC/S standards. Indian exporters aiming to supply LEK d.d. must ensure their manufacturing facilities are certified under these recognized GMP standards to comply with Slovenian regulations. (jazmp.si)

3Quality & Labeling

LEK D.D — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

LEK d.d.'s focus on importing specific therapeutic categories—Immunosuppressants, CNS & Psychiatric, and Cardiovascular—aligns with Slovenia's healthcare needs and market demand. The substantial import value of Tacrolimus, Gabapentin, and Valsartan indicates a strategic emphasis on these areas. The high concentration of imports in these categories suggests that LEK d.d. aims to address critical health conditions prevalent in the Slovenian population, thereby strengthening its market position.

2Sourcing Profile

LEK d.d.'s sourcing strategy is heavily centered on generic drugs, with a particular focus on formulations imported from India. The company's portfolio concentration, with the top five products accounting for 90% of imports, reflects a targeted approach to procurement. This strategy ensures a consistent supply of high-demand medications, leveraging India's manufacturing capabilities and cost advantages. However, the limited number of unique suppliers and formulations imported suggests potential opportunities for diversification and risk mitigation.

3Market Positioning

Based on its product mix, LEK d.d. serves multiple segments of the Slovenian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on essential therapeutic areas positions it to meet the needs of various healthcare providers and patients. By importing a significant volume of high-demand medications, LEK d.d. plays a crucial role in ensuring the availability of critical drugs across Slovenia.

Seller's Guide — How to Become a Supplier to LEK D.D

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with LEK d.d., particularly in therapeutic categories where the company seeks diversification. The current sourcing profile indicates potential gaps in LEK d.d.'s supply chain that new suppliers could fill. To capitalize on this opportunity, Indian exporters must demonstrate compliance with Slovenian regulatory standards, including GMP certifications and quality requirements. Building relationships through direct engagement and participation in tenders can facilitate entry into the Slovenian market.

2Requirements & Qualifications

Indian exporters aiming to supply LEK d.d. must obtain manufacturing authorizations that include import activities, as stipulated by Slovenian regulations. Compliance with recognized GMP standards—EU GMP, WHO GMP, or PIC/S—is mandatory. Additionally, adherence to Slovenian labeling requirements, including Slovenian language labeling and serialization mandates, is essential. Ensuring product quality through batch testing and stability assessments is also a critical requirement. (jazmp.si)

3How to Approach

Frequently Asked Questions — LEK D.D

What products does LEK D.D import from India?

LEK D.D imports 8 pharmaceutical products across 6 categories. Top imports: Tacrolimus ($10.7M), Gabapentin ($5.5M), Valsartan ($3.4M), Loratadine ($2.1M), Allopurinol ($1.7M).

Who supplies pharmaceuticals to LEK D.D from India?

LEK D.D sources from 2 verified Indian suppliers. The primary supplier is Sandoz Private Limited (100.0% of imports, $9.2M).

What is LEK D.D's total pharmaceutical import value?

LEK D.D's total pharmaceutical import value from India is $25.9M, based on 518 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does LEK D.D focus on?

LEK D.D imports across 6 categories. The largest: Immunosuppressants (41.1%), CNS & Psychiatric (21.2%), Cardiovascular (19.1%).

Get Full LEK D.D Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.